<DOC>
	<DOCNO>NCT02123264</DOCNO>
	<brief_summary>The progression structural joint damage lead cause disability socioeconomic cost associate rheumatoid arthritis ( RA ) . Remission low clinical activity always imply absence progression structural damage . The main objective study evaluate progression radiological damage early RA patient currently treat disease modify anti-rheumatic drug ( DMARDs ) low disease activity treatment zoledronic acid add . The investigator propose randomized clinical trial 94 patient RA le 2 year evolution , treat DMARDs , present criterion low disease activity ( DAS28 &lt; 3.2 ) . Patients randomize two branch : zoledronic acid treatment . The primary study endpoint progression radiological damage assess blinded way difference Sharp-van der Heijde index ( SHI ) radiographs hands foot two year ; secondary variable : radiographic progression one year , serum bone biomarkers ( OPG , RANKL , DKK-1 sclerostin ) adverse effect . In subgroup patient , investigator shall evaluate change size hand erosion multislice compute tomography evolution periarticular osteoporosis systemic bone mass dual X-ray absorptiometry ( DXA ) .</brief_summary>
	<brief_title>Zoledronic Acid Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Age equal great 18 year 2 . Patients RA le 2 year evolution 3 . DMARD therapy ( methotrexate alone methotrexate , leflunomide methotrexate within COBRA strategy ) stable dose least 6 week prior study entry 4 . Patients treated glucocorticoid stable dose prednisone 5 mg / day equivalent dose another glucocorticoid 5 . Low disease activity ( DAS28 &lt; 3.2 ) 6 . In case premenopausal woman , commitment make contraceptive treatment 3 year last dose zoledronic acid 7 . Signed informed consent 1 . Previous current treatment biological drug use treatment RA ( infliximab , adalimumab , etanercept , certolizumab , golimumab , rituximab , abatacept , tocilizumab ) 2 . Pretreatment : 1 . Bisphosphonates 5 year prior onset RA 2 . Calcitonin , raloxifene , bazedoxifene , strontium ranelate , teriparatide denosumab year onset RA 3 . Contraindication treatment zoledronic acid : 1 . Hypersensitivity bisphosphonates 2 . Hypocalcemia 3 . Glomerular filtration rate &lt; 35 mL / min 4 . Pregnant ( negative pregnancy test ) lactate woman 5 . Poor oral hygiene 6 . Pending invasive dental procedure 4 . Serum level calcidiol low 25 nmol/L ( 10 ng/mL ) . 5 . Simultaneous participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>